RPG Life Sciences Ltd reports Q2 FY27 revenue of ₹211.6 crore, up 16.5% year on year
- Adjusted EBITDA was ₹42.5 crore, with a 20.1% margin versus 21.0% a year earlier.
- Adjusted PAT rose 13.4% to ₹32.3 crore; adjusted PBT increased 15.0% to ₹50.1 crore.
- Adjusted figures exclude ₹5.5 crore of one-off restructuring and API acquisition costs.